Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giuseppe Lopalco

Showing results (111-120 of 221) with videos related to

Pageof 23
Sort By:
Frontiers in Medicine|December 30, 2021
Empowering Patients in the Therapeutic Decision-Making Process: A Glance Into Behçet's SyndromeDiana Marinello, Federica Di Cianni, Alessandra Del Bianco, et al.
Internal and Emergency Medicine|June 26, 2022
Relapses of idiopathic inflammatory myopathies after vaccination against COVID-19: a real-life multicenter Italian studyEdoardo Conticini, Miriana d'Alessandro, Silvia Grazzini, et al.
Clinical Rheumatology|August 13, 2018
Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patientsClaudia Fabiani, Antonio Vitale, Donato Rigante, et al.
Mediators of Inflammation|August 19, 2014
Untangling the web of systemic autoinflammatory diseasesDonato Rigante, Giuseppe Lopalco, Antonio Vitale, et al.
Clinical Rheumatology|March 25, 2014
Serum amyloid-A in Behçet's diseaseAntonio Vitale, Donato Rigante, Giuseppe Lopalco, et al.
Clinical and Experimental Rheumatology|April 4, 2019
Efficacy and safety of certolizumab pegol and golimumab in the treatment of non-infectious uveitisGian Marco Tosi, Jurgen Sota, Antonio Vitale, et al.
International Journal of Molecular Sciences|April 20, 2019
Unveiling the Efficacy, Safety, and Tolerability of Anti-Interleukin-1 Treatment in Monogenic and Multifactorial Autoinflammatory DiseasesAlessandra Bettiol, Giuseppe Lopalco, Giacomo Emmi, et al.
Clinical Rheumatology|May 17, 2018
Efficacy of adalimumab and infliximab in recalcitrant retinal vasculitis inadequately responsive to other immunomodulatory therapiesClaudia Fabiani, Jurgen Sota, Donato Rigante, et al.
Clinical and Experimental Rheumatology|February 6, 2019
Efficacy of anti-tumour necrosis factor-α monoclonal antibodies in patients with non-infectious anterior uveitisClaudia Fabiani, Antonio Vitale, Donato Rigante, et al.
Mediators of Inflammation|May 16, 2020
New Potential Weapons for Refractory Scleritis in the Era of Targeted TherapyClaudia Fabiani, Jurgen Sota, Maite Sainz-de-la-Maza, et al.
Pageof 23

Showing results (111-120 of 221) with videos related to

Sort By:
Pageof 23
Frontiers in Medicine|December 30, 2021
Empowering Patients in the Therapeutic Decision-Making Process: A Glance Into Behçet's SyndromeDiana Marinello, Federica Di Cianni, Alessandra Del Bianco, et al.
Internal and Emergency Medicine|June 26, 2022
Relapses of idiopathic inflammatory myopathies after vaccination against COVID-19: a real-life multicenter Italian studyEdoardo Conticini, Miriana d'Alessandro, Silvia Grazzini, et al.
Clinical Rheumatology|August 13, 2018
Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patientsClaudia Fabiani, Antonio Vitale, Donato Rigante, et al.
Mediators of Inflammation|August 19, 2014
Untangling the web of systemic autoinflammatory diseasesDonato Rigante, Giuseppe Lopalco, Antonio Vitale, et al.
Clinical Rheumatology|March 25, 2014
Serum amyloid-A in Behçet's diseaseAntonio Vitale, Donato Rigante, Giuseppe Lopalco, et al.
Clinical and Experimental Rheumatology|April 4, 2019
Efficacy and safety of certolizumab pegol and golimumab in the treatment of non-infectious uveitisGian Marco Tosi, Jurgen Sota, Antonio Vitale, et al.
International Journal of Molecular Sciences|April 20, 2019
Unveiling the Efficacy, Safety, and Tolerability of Anti-Interleukin-1 Treatment in Monogenic and Multifactorial Autoinflammatory DiseasesAlessandra Bettiol, Giuseppe Lopalco, Giacomo Emmi, et al.
Clinical Rheumatology|May 17, 2018
Efficacy of adalimumab and infliximab in recalcitrant retinal vasculitis inadequately responsive to other immunomodulatory therapiesClaudia Fabiani, Jurgen Sota, Donato Rigante, et al.
Clinical and Experimental Rheumatology|February 6, 2019
Efficacy of anti-tumour necrosis factor-α monoclonal antibodies in patients with non-infectious anterior uveitisClaudia Fabiani, Antonio Vitale, Donato Rigante, et al.
Mediators of Inflammation|May 16, 2020
New Potential Weapons for Refractory Scleritis in the Era of Targeted TherapyClaudia Fabiani, Jurgen Sota, Maite Sainz-de-la-Maza, et al.
Pageof 23